Differential effect of chemical compounds on Helicobacter pylori growth and subsequent apoptosis

CURRENT STATUS: ACCEPTED

Dharmendra Kashyap  
Indian Institute of Technology Indore

Buddhadev Baral  
Indian Institute of Technology Indore

Tarun Prakash Verma  
Indian Institute of Technology Indore

Charu Sonkar  
Indian Institute of Technology Indore

Debi Chatterji  
Choithram Hospital and Research Centre

Ajay Kumar Jain  
Choithram Hospital and Research Centre

Hem Chandra Jha  
Indian Institute of Technology Indore

Corresponding Author

hemcjha@iiti.ac.in

DOI: 10.21203/rs.2.16924/v1

SUBJECT AREAS  
Applied & Industrial Microbiology  General Microbiology

KEYWORDS  
Gastric cancer, Plaque control agent, CagA, Apoptotic pathway, Growth curve
Abstract
Background Helicobacter pylori (H. pylori) is well-known for its role in chronic gastritis and gastric cancer. Eradication of these carcinogenic bacteria from the gut is one of the major challenges for the clinicians. The complexity of treatment is mainly owing to, antibiotic resistance and relapse due to extra gastric reservoir in the oral cavity. Our study focuses on the isolation of H. pylori from distinct habitats (gastric biopsy and gastric juice) of the gut microenvironment and its subsequent characterization. Further, we have also evaluated the effect of various plaque control agents on isolated strains of H. pylori.

Results The strains isolated from two different habitats of the same subject shows a striking difference in their growth pattern. Promisingly, some included chemicals are effective in growth inhibition after recommended 30 sec treatment. The subsequent evaluation shows that chemical B (out of chemical A, B, C, D and E) is the most effective and downregulate the expression of CagA in the infected AGS cells.

Conclusion For the fast time, in our study the pylori isolated from different habitat of the same subject shows differential growth pattern. Nowadays, antibiotic resistance and relapse of H. pylori make it difficult to eradicate the bacteria from gastric as well as oral reservoir. Thus, this study may help to reduce the bacteria in their oral reservoir and also control the H. pylori migration from oral to gastric compartment.

Background

*Helicobacter pylori* play an important role in the development of various gastro-duodenal diseases [1]. Usually, it propagates inside the mucosal layer of the stomach, however, its significance as an obligate pathogen is still a question [2]. Possible symbiotic relationship with the host has been debated since its discovery [3]. How *H. pylori* cause gastric carcinogenesis pathogenesis is still unclear, in spite of several hypotheses [2]. Importantly, been good flora may producing bacteriocin-like inhibitory protein which can inhibit *H. pylori* growth [4]. However, due to any kind of loss in this good flora may increase in the number of *H. pylori*. Further, it leads to gastric acid production and ulceration [5]. Some strains of *H. pylori* are virulent and host factors may also responsible for disease progression [6]. Additionally, other bacteria which are acid-tolerant might also reside at the infection site within ulcers and thus enhance the problem caused by *H. pylori* [2].
Worldwide, *H. pylori* have been classified according to population genetics tool (STRUCTURE) developed by Pritchard et al [7]. Broadly, they represent geographical areas and named as: *hpEurope, hpSahul, hpEastAsia, hpAsia2, hpNEAfrica, hpAfrica1* and *hpAfrica2* [8]. Also, there is a large variability in the incidence of gastric cancer worldwide [9]. Asian countries such as South Korea, China and Japan have a high incidence of gastric cancer. India is a low risk country for gastric cancer, however, it might be because of underreporting [10]. There lies a lacuna in the epidemiological studies from small towns and villages which represents a large part of the Indian population. *H. pylori* seroprevalence in the adult population of developing countries varies from 55% to 92%. In contrary to this, the seroprevalence of *H. pylori* in Chinese and Japanese adults is 44% and 55%, respectively [11]. The primary manifestation of *H. pylori* in India is the duodenal ulcer, which is a major concern in India [12]. A study suggested that 56% of *H. pylori* infection in gastric cancer [13]. Therefore, a comprehensive study of *H. pylori* strains and its pathogenic properties in Indian scenario is needed.

*H. pylori* may be transmitted through oral-oral or oro-fecal route, and thus oral cavity may act as its possible reservoir [14]. Its presence in the oral cavity is seldom eliminated by *H. pylori* eradication therapy. Moreover, oral site may act as a source for reinfection [15]. Hence, its eradication from oral microenvironment is important [16, 17]. Several antimicrobial (e.g. bisbiguanides, metal ions, phenols, quaternary ammonium compounds, etc.) and antiplaque agents (e.g. surfactants, essential oils) in the form of toothpaste and mouth rinses have been formulated [18]. Antiplaque agents are destroying bacterial biofilm which suppresses subsequent reinfection. In contrast, antimicrobial agents inhibit the growth or kill the target bacteria [19].

More virulent strains of *H. pylori* harbor numerous adhesins (BabA/B, SabA, AlpA/B, OipA and HopZ) and the *cag* (cytotoxin-associated genes) pathogenicity island encoding a type IV secretion system (T4SS) [20]. A tight bacterial contact with the host cell is established by the adhesins [21]. Further, bacterial effector proteins like CagA is delivered into host cells through this secretion system [22]. A study reported that *H. pylori* colonization may also depend on the alteration of mucosal epithelial apoptosis while doing so by chronic inflammation [23]. Surprisingly, the relation between various
serotypes, their growth, alone or with gastric epithelial cells and possible occurrence in gastric cancer has not been evaluated till date. Investigation of *H. pylori* strains for their growth and subsequent host cell transformation ability may open better understanding in this domain. Hence, the present study was designed to evaluate the growth pattern of various clinically isolated strains of *H. pylori* and their response to treatment with commercially available chemical plaque control agents. The study also includes the evaluation of tumor suppressor and proto-oncogenes status in host cells as a response to treated and untreated strains of *H. pylori*.

Results

**Gastric biopsy and juice collection from gastritis patients for isolation of clinical strains of *H. pylori***

Till date, there is no *H. pylori* strain reported from central India to the best of our knowledge. Moreover, strains from northern and southern India have been listed in previous reports [24]. Interestingly, none of the studies from India has evaluated the association between gastritis or gastric cancer progression and pathogenic *H. pylori* strains. *H. pylori* were successfully isolated from five out of 14 biopsy samples and four out of 11 juice samples (Table 1). After observation on selective media, gram staining was performed for all isolates (Fig. 1). Further, three clinical strains of *H. pylori* isolated from biopsies and one from juice were subjected for the amplification of *H. pylori* (CagA) through qRT-PCR (data not shown). Further validation of the clinical isolates was confirmed through nucleotide sequencing (data not shown).

**The growth pattern of different clinical isolates of *H. pylori***

Growth curve of confirmed strains of *H. pylori* was determined by recording OD at 600nm at various time points (0, 2, 6, 12, 18 and 24 hrs) and a curve was plotted (Fig. 2 a). Our results revealed that the growth of two clinical strains namely HB1 and HB5 was significantly faster compared to the other seven clinical and one reference strain (I10). Interestingly, HB1 and HB5 have similar but not identical growth pattern at all examined time point (fig. 2 b). It is also fascinating that the growth pattern of HB1 and HJ1 was quite different, even though they were isolated from the same gastritis patient (fig. 2 b). Other clinical strains (HB4, HJ9, HJ10, HB10, HJ14 and HB14) shows a similar growth pattern as
I10 until 24 hrs.

To have a better understanding of growth pattern, we calculated fold change in growth compared to reference strain I10 (Fig. 2 b). These graphs are plotted in the form of bar chart at all recorded time points (0, 2, 6, 12, 18 and 24 hrs). Three to five folds faster growth was observed in HB1 and HB5 compared to I10 at 2 hrs and further, it is increasing up to 24 hrs. Moreover, strains such as Hj1, HB10, and HB14 were showing moderately higher growth (3 to 5 folds) compared to reference strain I10 from 6 hours onwards. Importantly, the growth of HB1 and HB5 were steadily increasing to 18 hrs. Hence, our study reflected two fast growing strains (HB1 and HB5) compared to other clinical isolates HB4, Hj9, Hj10, HB10, Hj14, HB14, Hj14 and reference strain I10.

**Confirmation of chemical plaque control agents through LCMS**

The chemical composition of the selected plaque control agents is reconfirmed through LCMS (Supp. Fig 2). Sophisticated Instrument Centre facility at IIT Indore was used for these two chemical identification techniques. Active components in the plaque control agents of A, B, C, D, and E were determined through LCMS. Hence, LCMS characterization validates the labeled active components in plaque control agents.

**The growth pattern of selected clinical strains of H. pylori with chemical treatment**

All chosen chemicals recommend 30 sec oral rinsing for effective plaque control. Further, our two fast growing (HB1 and HB5), two slow growing (Hj9 and HB14) and a reference strain (I10) were selected for this experiment (Fig. 2 a, b). Interestingly, we observed that chemical A and C were not able to stop the growth of fast growing strain even after 30 sec treatment (Fig. 3 a). Although, growth of fast growing strain were accelerated after 2 hrs treatment with chemical A and C while chemical B, D, and E were able to inhibit the growth until 24 hrs post-treatment. Additionally, slow growing strain such as Hj9 and HB14 were not able to grow until 12 hrs with all used chemicals (Fig. 3 b). However, these strains start growing from 12 hrs onwards when treated with chemical C (Fig. 3 b). Notably, our reference strain, I10, has not shown any growth after treatment with all chemicals until 24 hrs (Fig. 3 b). In all these experiments, we have used untreated strains as positive controls. Also, we had included culture media as a negative control. No substantial growth was observed for I10 when bar
In this study, we have found that chemical A was least efficient in the control of HB1 growth followed by chemical C. The substantial growth of HB1 was observed from 6 hrs onwards while treated with chemical A. Furthermore, when HB1 treated with chemical C was able to grow 12 hrs post-treatment (Fig. 3 d). Moreover, the growth of another fast growing strain, HB5, treated with chemical A and C was suppressed until only 2 hrs (Fig. 3 e). We observed considerable growth of HB5, 6 hrs onwards in A and C treatment. Importantly, chemical B, D, and E were able to suppress the growth of HB1 and HB5 until 24 hrs in this study (Fig. 3 d, e).

**Selective oral rinse are restricting *H. pylori* growth even at shorter exposure**

Oral rinse B, D, and E were found to be effective in controlling the growth of slow as well as fast growing strains at 30 sec treatment. Hence, we investigated these selected chemicals alone (B, D, and E) and in combination (BD, BE, DE, and BDE) for a shorter duration of treatment (5 sec) compared to recommended 30 sec (Fig. 4 a, b). Even the 5 sec treatment to fast growing strains with all effective chemicals alone and in combination were able to restrict the growth until 2 hrs (Fig. 4 a). Surprisingly, data recorded 6 hours post-treatment were demonstrating the growth of HB1 and HB5 with D, E and their combinations. Importantly, all groups in which chemical B is included shows to be restricting the growth of HB1 and HB5 (Fig. 4a). Interestingly slow growing strains HJ9, HB14, and reference strain I10 growth completely abolished with all above chemical combinations till 24 hrs (Fig. 4b). Moreover, when we treated these chemicals for 10 sec alone and in combination, a similar pattern was found as with 30 sec (Suppl. Fig 1). We also plotted bar graph representing fold change in growth compared to control at different time points (0, 2, 6, 12, 18 and 24 hrs) for clearer outlook Fig. 4-c, d, e).

**The growth pattern of *H. pylori* after chemical treatment on BHI Agar plate:**

In addition to chemical treatment in liquid culture, we further evaluated the growth pattern on a BHI agar plate after 30 sec treatment with the selected chemicals. Representative pictures of chemical treated *H. pylori* strains are shown in fig. 5 a, b, c, d, e. The images were quantified using Image J (NIH) and graphs were plotted (Fig. 5 f, g, h, i, j). As expected, chemical treatment of C was not
effective and *H. pylori* growth was observed in the case of fast growing HB1 and HB5 after 12 hrs (Fig. 5 a, b, f, g). Moreover, we also witnessed growth after 24 hrs for slow growing strains (I10, HJ9, and HB14). Surprisingly, no growth was observed in the case of chemical A treatment in all the strains, contrary to the growth in liquid culture (Fig. 5). As expected, no growth was observed after treatment with chemical B, D, and E at all the recorded time points.

**Gene profiling of specific gastric cancer marker and *H. pylori* after chemical treatment**

Expression of *H. pylori* genes namely 16s rRNA, Cag A, and Bab A were investigated in this experiment. Additionally, reported gastric cancer marker such as CCND1, CDX2, PTEN[25], and MMP7 were also included [25–28]. The mixed expression profile was observed on treatment with chemicals (B, C, D, and E) for 5 sec in I10 strain. On treatment with chemical B, *H. pylori* (16s rRNA, CagA and BabA) and GC markers (CCND1, PTEN, and MMP7) were downregulated. However, expression was higher in CDX2 with 5 sec treatment to *H. pylori* followed by 12 hr incubation with gastric epithelial cells (AGS). *H. pylori* genes, 16s rRNA and Cag A are downregulated with the treatment of C and E (except HJ9) while Bab A was downregulated with C (Fig. 6 c, e). Moreover, PTEN and MMP7 were downregulated with chemical B, C, and E (Fig. 6 k, m). Interestingly, 30 sec treatment to I10 was able to abolish the expression of 16s rRNA; CagA; and BabA with chemical B; B, C, D and E; and B, C, and E respectively (Fig. 6 b). Our results also revealed that expression of CDX2; and MMP7 were higher with chemical B, C and D; C, D, and E respectively with the 30 sec treatment at 12 hrs time point (Fig. 6 j, n). Similarly, when we treated another slow growing strain HJ9 for 5 sec with chemicals followed by incubation with AGS, we observed a mixed response in gene expression profiling. In case of PTEN; and MMP7, the expression is moderately enhanced with chemical C, D, and E; B, C, and D respectively. Whereas, chemical B and E were able to diminish the expression of PTEN and MMP7 respectively (Fig. 6 l, n). 30 sec treatment of chemical B to the same strain followed by incubation shows slight downregulation in the expression of 16s rRNA, CagA, BabA, CCND1, CDX2, and PTEN. However, expression of MMP7 was an exception (Fig. 6). Further, when we treated HB14, another slow growing strain, for 5 sec with chemicals followed by incubation with AGS, we observed that CagA, BabA, CCND1, CDX2, and MMP7 were considerably downregulated with chemical B (Fig. 6). Additionally,
CCND1, CDX2, and MMP7 were minimally expressed with the treatment of B, C, and E, while PTEN is downregulated with E (Fig. 6). Moreover, when we treated HB14 for 30 sec and incubated with AGS we observed downregulation of CCND1, CDX2, and PTEN with C, D, and E, while expression of MMP7 was unregulated with C, D, and E (Fig. 6 n). However, CagA was abolished with B, C, and D (Fig. 6). Furthermore, results reflect varied gene expression profile with the treatment of 5 and 30 sec in fast growing strain HB1 (Fig. 6). Expression of CagA; and BabA were downregulated with the treatment of B, D, and E; and B, C, D, and E respectively (Fig. 6 c, d, e, f). Whereas, the expression of CCND1; CDX2; and MMP7 were enhanced with B, C, D and E; E; and B respectively (Fig. 6 g, h, i, j m, n). Treatment for 30 sec to HB1 shows minimal expression of CagA with chemical B, C, and D, while; MMP7 was upregulated with all the chemicals (Fig. 6 d, n).

**Status of apoptotic gene expression**

Earlier studies have classified cells as live, apoptotic and necrotic after EB/AO staining [29]. We investigated these cells (live, apoptotic and necrotic) on infection with 30 sec chemical treated *H. pylori* (Fig. 7). Additionally, evaluation of apoptotic pathways such as intrinsic/extrinsic/independent was performed through qRT-PCR, after treatment with these chemicals for 5 and 30 sec (Fig. 8). 5 sec exposure of chemical D in I10 strain was able to enhance the expression of APAF1, BID and BAK (Fig. 8 c, e, g). Interestingly, I10 treated with chemical C and incubated with AGS cells were able to suppress all studied apoptotic genes (Fig. 8). Whereas, other chemicals were not able to change the expression pattern of these genes considerably. Further, 30 sec treatment of I10 and incubation with AGS cells show a different pattern (Fig. 8). I10 treated with chemical B was able to reduce the expression of all the selected genes except FADD (Fig. 8). However, treatment with chemical D and E were slightly enhancing the expression of all pro-apoptotic genes (Fig. 8).

Furthermore, when we applied these chemicals for 5 sec on Hj9 and incubated with AGS cells, we witnessed an upsurge in APAF1 expression, while BCL2 was downregulated except in chemical D (Fig. 8 c, m). Surprisingly, 30 sec treatment of Hj9 reflected a varied gene expression compared to 5 sec. Chemical C, D, and E with 30 sec exposure were able to up-regulate all apoptotic genes except NOXA and PUMA (Fig. 8). However, expression of anti-apoptotic BCL2 was reduced with chemical B (Fig. 8).
Application of these chemicals for 5 sec on HB14 followed by incubation with AGS cells demonstrated that chemical D up-regulates all pro-apoptotic genes (Fig. 8). Interestingly, treatment with B was able to enhance extrinsic apoptotic regulator FADD and reduce the expression of all used intrinsic markers. It also diminished the expression of BCL2 (Fig. 8), fascinatingly, all apoptotic markers except PUMA were considerably down-regulated with the 30 sec treatment of chemical D (Fig. 8). Moreover, the expression of FADD, APAF1, and BAK, were also reduced with chemical E (Fig. 8 b, d, f).

Furthermore, fast growing strain HB1 was treated for 5 sec and incubated with AGS for the detection of apoptotic and anti-apoptotic genes. Here, chemical C and E were slightly up-regulating the expression of FADD, APAF1, BID and BAK (Fig. 8 a, c, e). In addition to this, chemical B treated cells were able to up-regulate FADD, APAF1, BID and NOXA (Fig. 8 a, c, g, k). Treatment of chemical C for 30 sec to the same strain showed up-regulation of FADD, BID, and PUMA (Fig. 8 b, h, j). In contrary to this, slightly up-regulation was observed for BCL2 in all chemical treatment.

Discussion

Various studies suggested the association between \textit{H. pylori} and gastric carcinogenesis [1]. Infection of \textit{H. pylori} in less developed Asian countries like India, Pakistan, Thailand, and Bangladesh is more prevalent than in more developed Asian countries like Japan and China. Interestingly, the occurrence of gastric cancer is lower in less developed Asian countries compared to Japan and China [11]. Similar enigma has been reported from African nations as compared to the Western countries [30].

Prevalence of \textit{H. pylori} infection and the occurrence of gastric carcinogenesis does not appear to be proportionate around the world [9]. This may be attributed to the variations in the \textit{H. pylori} strain pathogenicity and other associated risk factors for gastric carcinogenesis. It is important to understand the discrepancy in \textit{H. pylori} pathogenicity due to geographical and host anatomical location.

In the present study, we were able to demonstrate significantly different growth patterns of isolated \textit{H. pylori} collected from gastric biopsy and juice samples. These findings motivated us to validate the growth pattern of various clinical \textit{H. pylori} strains through plate densitometry. The \textit{H. pylori} isolation
from two different niches of the same person may also lead to the differential growth pattern. For the first time, our study revealed that \textit{H. pylori} isolated from the biopsy grow aggressively compared to the gastric juice of the same subject. For example, HJ1 and HB1; HJ10 and HB10; and HJ14 and HB14 were isolated from two different niches of the same subjects. There was a significant difference in the growth pattern of HJ1 and HB1, which was not remarkable in the case of HJ10 and HB10 as well as HJ14 and HB14. This finding demonstrates the importance of infection site and their microenvironment for \textit{H. pylori} dependent disease progression. Hence, these results show a specific pattern for the adaptation of \textit{H. pylori}, which may act as a milestone in disease progression and subjected to further investigation.

Earlier, Marshall et al showed that \textit{H. pylori} eradication resulted in rapid gastric ulcer healing (92% vs. 61%) and lower relapse rate (21% vs. 84) than non-eradication [31]. Importantly, resistance to antibiotic treatment is one of the major causes for the development of primary \textit{H. pylori} infection to chronic gastritis and gastric cancer [32]. Studies reported that \textit{H. pylori} isolated from Indian population are resistant to its specific antibiotics [33]. Additionally, some strains of \textit{H. pylori} are also resistant to the triple therapy which further increases the complication in eradication procedure [34]. Transmission mode of \textit{H. pylori} is oral-oral or oro-fecal route [35]. Therefore oral cavity may serve as a reservoir for \textit{H. pylori} (Gebara et al., 2006). Earlier studies demonstrated that relapse of \textit{H. pylori} infection is mainly due to the presence of its extra gastric reservoir in the oral compartment [36]. Hence, eradication of \textit{H. pylori} in the mouth may help in restricting its transmission and relapse from mouth to stomach [17]. In our study, the approach is to eliminate \textit{H. pylori} in oral microenvironment using mouth rinses. It will further help in treating the infection and will enhance the treatment outcome in gastric abnormalities.

Various antiplaque and antimicrobial agents are known for inhibiting the growth or killing the target bacteria present in oral microenvironment. Chemical plaque control agents may consist of chlorhexidine [37], essential oil [38], cetylpyridinium chloride [39], povidone-iodine [40], etc. In our study, we investigated the effect of these chemicals on \textit{H. pylori} growth and its carcinogenic abilities. Based on the growth curve analysis of various clinical isolates, we selected two fast (HB1 and HB5)
and two slow growing strains (HJ9 and HB14), along with one reference strain I10, for further study. Chemical B, D, and E were effective in fast growing strains with 30 sec incubation. In contrary to this, oral rinse A and C act as bacteriostatic and inhibit the growth until 2 hrs. Additionally, in the case of slow growing strains (HJ9 and HB14) all used chemicals except C are effective. While chemical C act as bacteriostatic up to 12 hrs. Interestingly, all used chemicals were found to be efficient to kill reference strain I10, which has been grown for a long time in laboratory conditions. There is a need for further investigation of differential chemical response in clinical isolate vs. lab reference strain even though their growth patterns are similar.

To further validate the above experiment, plate densitometry was performed. It was observed that the growth of fast growing strains (HB1 and HB5) with the treatment of chemical C was detected at 2 hrs of liquid culture same as wild type, while 12 hrs of plate densitometry in comparison to 6 hrs of wild type. The growth of isolated strains (HJ1, HB4, HJ9, HB10, HJ10, HB14, and HJ14) was similar to the reference strain I10 whereas, strikingly HB1 and HB5 shows about 15 fold higher growth after 12 hrs. Although, these fast growing strains reflect higher growth at 2 and 6 hrs by 4 and 9 folds respectively.

Importantly, the growth of HB1 and HB5, which was observed with chemical A treatment in liquid culture, was not visible in the plate densitometry. Moreover, the growth of wild type fast growing strains could be detected within 2 hrs in liquid culture compared to 6 hrs in plate densitometry.

The use of oral rinse is a common practice but prolonged and repetitive use of these chemicals has an adverse effect on the user [41, 42]. A study conducted by McGaw & Belch shows negligible toxicity associated with the use of chlorhexidine mouth rinses through radiolabeling methods [43]. However, such studies were conducted in the ‘80s, hence, further investigations with modern detection techniques are needed in long term follow-up. Investigation on povidone-iodine, reveals that it can cause acute renal failure, especially when absorbed through mucosal surfaces [44, 45]. Even dilute solutions of povidone-iodine (0.1 to 20%) are toxic to human fibroblasts, granulocytes, and monocytes [46]. Toxicity of another chemical, cetyl pyridinium chloride, is noticed with vomiting, diarrhea, and abdominal pain. Ingestion of this chemical solution in concentrated form may produce burns of the
mouth, pharynx, and esophagus [47]. Additionally, hemorrhagic GI tract necrosis and peritonitis have also been reported [47]. Prolonged exposure of common constituents of oral rinses like essential oils, menthol, thymol, etc. can act as potential allergens in various ethnical races [48]. Moreover, some manufacturers produce alcohol-based mouthwashes which can cause complications like irritation of oral mucosa and may be hazardous if ingested accidentally during pregnancy [49].

Our focus in this study was to reduce the time of exposure to minimize the possibility of toxicity caused by these chemicals. To achieve our goal, we performed the 5 sec treatment and compared it with 30 sec treatment of *H. pylori*.

We selected those chemicals which were effective in the 30 sec treatment in combinations and alone. As expected, growth of slow growing strains (I10, HJ9, and HB14) was controlled through all used chemicals at 5 sec incubation. However, only chemical B and its combination seem to be potent for all *H. pylori* strains. Strikingly, chemicals D and E, which were effective on 30 sec treatment, were unable to show comparable results with fast growing strains. The high efficacy of chemical B may be attributed to its large dicationic molecule (Chlorhexidine) which can adsorb onto negatively charged bacterial cell walls [50]. This increases the permeability of the inner membrane and leads to the leakage of low molecular weight components. At concentration 0.2 %, this damage is permanent and hence act as a bactericidal agent [50].

Further, in our study we evaluated the genes like CCND1, CDX2, PTEN, and MMP7 which are related to *H. pylori* mediated gastric cancer progression.

The cag pathogenicity island (cag-PAI) is one of the major virulence determinants of *H. pylori*. Irrespective of the growth pattern variation in isolated *H. pylori* strains, there is significant downregulation of CagA gene with chemical B. Also long exposure of C and D to I10, HB14, and HB1 diminish the expression of CagA. Here Cag A expression imitates the growth of *H. pylori* after chemical B treatment.

EB/AO staining has been used as a gold standard to differentiate between live, apoptotic (early/late) and necrotic cells. We observed that *H. pylori* treated with chemical B and incubated with AGS shows more cells in the late apoptotic stage. While with chemical C, D and E treatment, cells are either in
early apoptotic stage or live. This reflects that chemical B is most effective among all the studied chemicals.

To understand the growth arrest of *H. pylori* through used chemicals, we have mapped several mechanisms of cell death mainly apoptosis and necrosis. In brief, we have observed genes regulated for apoptosis by the intrinsic, extrinsic or independent pathways. Interestingly, extrinsic apoptotic marker FADD is slightly enhanced in slow growing strain HJ9 and HB14 with selective chemicals. Although, studies suggest that FADD is expressed on the surface of cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells as part of their armamentarium against infected or transformed cells.

Moreover, markers for the intrinsic pathway, APAF1 shows higher expression during shorter exposure of chemical B, C, D, and E to HJ9, while the result is not similar for longer exposure. Notably, BID shows selective up-regulation with chemical D in slow growing strains. Studies have demonstrated that both APAF1 and BID belongs to the BCL2 family and act with the mitochondria-related apoptotic pathway [51, 52]. However, expression pattern for BAK, PUMA, and NOXA was not decisive with used chemicals for all included *H. pylori* strains. PUMA and NOXA belong to pro-apoptotic BH3 only family which regulates BCL2 activity [53]. Interestingly, anti-apoptotic gene, BCL2, was noticeably down-regulated in 5 sec treatment while not in 30 sec with the applied chemicals.

**Conclusion**

*H. pylori* adaptation to varying physiological habitat in the host may be responsible for the differences in its growth and pathogenicity. For avoiding the challenges of relapse and antibiotic resistance we used chemical formulations and found that these are effective against CagA. Some of the changeability in outcome can be attributed to different bacterial strain specificity, host susceptibility, and the type of response elicited in the infected host. There is a need for detailed study about the molecular pathways modulated by the chemical in bacteria. These studies will also open wide scope to apply various bactericidal chemical combinations for the treatment and eradication of *H. pylori* infection.

**Materials And Methods**

**Patient recruitment:**
The endoscopic procedure was performed after getting informed written consent from the patients. The protocol for the present study was approved by the ethical committee of the Indian Institute of Technology Indore, as well as Choithram Hospital Indore (approval number FD090) and all procedures were performed by following the revised declaration of Helsinki 2000. We collected only Rapid Urease Test (RUT) positive 14 biopsies (male= 9 and female=5) and 11 gastric juice (male=6, female=5) samples from gastritis patients (Table 1). Patients undergoing antibiotic treatment against H. pylori were excluded for sampling. Moreover, for the further processing, biopsy samples were immediately placed in a microcentrifuge tube containing Brucella broth (BD Difco Cat No. 8806541) with 20% glucose (Hi-media, Cat No. TC130), while gastric juice was collected in sterile 15ml centrifuge tube. Samples were transported to IIT Indore in ice.

**Table 1: Gastric biopsy and juice collection from gastritis patients**

| Sr. No. | Sample | Sex | RUT status | Grown sample |
|---------|--------|-----|------------|--------------|
|         | HB     | HJ  |            |              |
| 1       | ü      | ü   | F          | +            | HB1          |
| 2       | ü      | ü   | M          | +            | HJ1          |
| 3       | ü      | ü   | M          | +            | -            |
| 4       | ü      | ü   | M          | +            | -            |
| 5       | ü      | ü   | M          | +            | HB4          |
| 6       | ü      | ü   | M          | +            | -            |
| 7       | ü      | ü   | M          | +            | -            |
| 8       | ü      | ü   | F          | +            | -            |
| 9       | ü      | ü   | F          | +            | -            |
| 10      | ü      | ü   | M          | +            | HB10         |
| 11      | ü      | ü   | M          | +            | HJ10         |
| 12      | ü      | ü   | M          | +            | -            |
| 13      | ü      | ü   | F          | +            | -            |
| 14      | ü      | ü   | F          | +            | HB14         |

RUT- Rapid Urease Test, HB- Gastric Biopsy, HJ- Gastric Juice, M- Male, F- Female
Culturing of *H. pylori* from clinical samples

The biopsy samples were homogenized by using a glass rod. One loopful of the homogenous sample was streaked on Columbia agar plate (Himedia ME144) containing the *H. pylori* selective antibiotics, (5mg/L cefsulodin, 10mg/L vancomycin, 5mg/L amphotericin B, 5mg/L trimethoprim and 10% defibrinated blood, BD, Cat. No. 254005). The plates were incubated in a microaerophilic chamber (Whitley DG 250) containing specific growth condition (i.e. 85% N₂, 10% CO₂ and 5% O₂) at 37°C. The same procedure was followed for gastric juice samples and the colonial growth was observed for the next 3-4 days. *H. pylori* isolated form biopsy and gastric juice samples were named as HB and HJ respectively, followed by a number representing the sequence of sampling. In the present study, we also used I10 as a reference *H. pylori* strain which was kindly gifted by Dr. Ashish Kumar Mukhopadhyay from the National Institute of Cholera and Enteric Diseases (NICED) Kolkata.

Culturing of clinical isolates in liquid and solid growth medium

From each sample, a single colony was picked from the Columbia agar plate and inoculated in brain heart infusion media (BHI, Cat. No. 237500- BD Brain Heart Infusion broth), containing 10% Fetal Bovine Serum (FBS Hi-media, Cat. No. RM-10432) with 3X *H. pylori* selective antibiotics in a snap cap tube (BD, Cat. No. 352001). Simultaneously, it was also streaked on a BHI agar plate containing the same concentration of FBS and antibiotics. Both broth and plate were incubated in a similar growth condition as described above.

Gram staining:

To identify isolated strains, gram staining was performed. Preparation of smear was done after suspending fresh culture in 100µl PBS followed by air-drying and heat-fixation over the flame. The smear was flooded with crystal violet for 60 seconds and the excess stain was washed off with distilled water. The smear was again flooded with gram iodine for 60 seconds. It was then rinsed with distilled water and blot dried followed by counterstaining with safranin for 30 seconds. The slides were again washed and observed under the microscope (100X - oil immersion lens) (Nikon Eclipse E100 upright microscope) (Fig. 1).

Growth curve:
The isolated *H. pylori* strains were analyzed for the growth pattern until 24 hrs. In brief, the isolates were cultured in a 14ml round bottom snap cap tube (BD) in biological duplicates by setting initial OD$_{600}$ 0.05 which correspond to approximately 80 million CFU per ml [54]. Further, they were incubated in the microaerophilic chamber as mentioned above. 150µl grown culture was placed in duplicate in 96 well flat bottom plate and OD were recorded at 600nm (Synergy H1 Hybrid Multi-Mode Reader, BioTek). Final OD value was normalized with media as a negative control.

**DNA isolation:**

*H. pylori* culture was harvested in phosphate-buffered saline for DNA extraction at OD$_{600nm}$ of 0.2-0.6. The pelleted cells were suspended in extraction solution (10mM Tris pH 8.0, 15mM NaCl, 10mM EDTA, 0.5% SDS) and kept at 55°C for 1 hrs. Proteinase K (Thermo fisher scientific) solution (20 mg/mL) was added (1mg/ml) and samples were incubated overnight at 37°C. RNase-A (Himedia) was added (0.1 mg/ ml) to the solution and kept at 37°C for 1hr. The DNA was extracted with the phenol-chloroform-isoamyl-alcohol method [55].

**PCR detection:**

*H. pylori* DNA samples were amplified by Platinum™ Taq DNA Polymerase (Invitrogen™, Cat. No.10966026). The reaction volume for PCR was 50 µL (50 mM KCl, 1.5 mM MgCl$_2$, 200 mM dNTPs, 10 mM Tris-HCl (pH=8.3), 10 pmol primer, 2.5 units Taq polymerase and 100 ng of DNA template). CagA specific forward primer 5′GCCATCATGTTTTAGCCTACC3′ and reverse primer 5′GAGCGCCTAGGGAAATGATC3′ respectively were used for amplification (product size -183 bp). The amplification was carried out with initial denaturation at 94°C for 7 minutes followed by 40 cycles of denaturation, annealing, extension and final extension at 94°C for 2 minute, 55°C for 30 sec, 72°C for 30 sec and 72°C for 10 minutes respectively. Analysis of the amplified products were done by gel electrophoresis using 2.5% agarose gel and stained with 0.5 µg/ml ethidium bromide. Product size was confirmed by using 50-bp DNA ladder (Hi-Media, cat no.MBT130). The image of gel was acquired on a gel documentation system (ImageQuant LAS 4000, GE Healthcare Life Sciences).

**Chemical plaque control agents:**
Five different commercially available mouthwash solutions were purchased from local pharmacy store and were assigned name A, B, C, D & E. Mouthwash A contains cetylpyridinium chloride 0.075% w/w, mouthwash B contains chlorhexidine (0.2% w/v), mouthwash C contains naturally derived clove oil (0.1mg/gm) (cloves extracts), mouthwash D contains thymol (thyme) 0.064%, methyl salicylate (wintergreen) 0.06% and eucalyptol (eucalyptus) 0.092%, and mouthwash E contains 2% w/v povidone-iodine.

**LC-MS:**

Mass and spectral analysis were done by Bruker Daltonik, Benchtop, High-Performance Electrospray Ionization Quadrupole time-of-flight LC-MS spectrometer designed for estimation of an exact mass of the components present in mouthwash solutions. The bactericidal function of cetyl-pyridinium chloride (CPC) or 1-hexadecylpyridinium chloride, or chlorhexidine gluconate (CHG), clove oil, menthol/thymol and povidone/iodine is well known and used in various antibacterial products like mouthwashes, throat sprays, nasal sprays. We have got exact mass spectra at 304.5, 253, 205.1, 212.1 and 102.12 for CPC, chlorhexidine, clove oil, thymol and povidone/iodine respectively.

**H. pylori growth inhibition by mouthwash:**

Povidone-iodine (2%) was diluted in water (1:1), while other mouthwashes were used in provided concentrations. A fixed number of *H. pylori* (6 x 10⁷) were incubated with 1 ml of all mouthwashes for 30 sec, 10 sec and 5 sec, followed by centrifugation at 3000 rpm for 5 min. The control group was left untreated. Pellets were suspended in 0.5 ml of BHI media containing 10% FBS and selective antibiotics followed by incubation in microaerophilic conditions as mentioned above. Optical density was taken at 600nm in 96 well plates. 150 µl of culture was taken in each well in duplicates (Synergy H1 microplate reader, Biotek). The growth curve was plotted at 0, 6, 12, 18, and 24 hrs time points.

**Densitometry of H. pylori growth on BHI agar plate**

Plate densitometry study on a BHI agar plate was performed to validate the experiments in the liquid medium. To check the growth of *H. pylori* (HB1, HB5, Hj9, HB14, and I10) on BHI agar plate, 1X10⁷ bacteria were taken (OD₆₀₀ 0.3 represents 500 million CFU per ml) [54] and suspended in 100 µL of
BHI broth and then spread by using glass spreader. Further, images of plates were obtained at 0, 6, 12 and 24 hrs and data were analyzed by measuring the mean grey value using Image J (NIH). In addition to this, the growth of bacteria on a BHI agar plate after 30 sec chemical treatment was also determined. 0.5X10^7 bacteria were taken and subjected to centrifugation at 3000 rpm for 5 min. The supernatant was discarded and the pellet was treated with 333 µL of the selected chemicals (A, B, C, D, and E) for 30 sec, the treatment was stopped by centrifugation at 3000 rpm for 5 min and the supernatant was discarded. The pellets were suspended in 50µL of BHI broth and spread in half of the plate and incubated in a microaerophilic condition followed by taking an image at various time intervals. We have shown BHI plates containing *H. pylori* growth and further, for better understanding we calculated the fold change in growth. The obtained data was plotted into graph fig.2 (c, d) and fig.5.

**RNA isolation and gene expression study through qRT-PCR**

Fixed number (6X10^7 CFU per mL) of *H. pylori* isolates (I10, HJ9, HB14, HB1) were treated with 1ml of oral rinse for 30 sec and 5 sec. Here, oral rinse A was excluded from cell culture study because of alcoholic constituents. Further, *H. pylori* isolates were incubated with AGS (Adenocarcinoma Gastric) cells under specific conditions (5% CO₂, 37°C) for 12 hrs. At 12 hrs time point, the pellet was collected by centrifugation (1600 rpm for 5 min) and washed twice with PBS. Total RNA was isolated by using Ribozol reagent (VWR™ Cat No. N580) as per the manufacturer’s instruction. cDNA was synthesized using superscript II reverse transcriptase kit (Takara, Cat No. RR820Q) according to the manufacturer’s instruction. Quantitative real-time PCR analysis was performed using the AriaMx Real-Time PCR System (Agilent technologies 5301 Stevens Creek Blvd Santa Clara, CA 95051 USA), for assessment of gastric cancer marker genes (CCND1, CDX2, PTEN, and MMP7), apoptotic genes (FADD, APAF1, BID, BAK, NOXA, PUMA and BCL2) and pathogen-associated genes (CagA, BabA and 16s-rRNA), (sup. table).

**Ethidium bromide and acridine orange (EB/AO) assay**

EB/AO dual staining was performed for the assessment of the apoptotic, necrotic and live-cells after
infection with chemically treated H. pylori. The experiment was performed in duplicates and the image was acquired by confocal microscopy (Olympus IX83) at 10X with 3X zoom in triplicates. The working concentration of acridine orange and ethidium bromide was 100µg/ml each [56].

Abbreviations
HB- Human Gastric Biopsy, HJ- Human Gastric Juice.

Declarations

**Ethics approval and consent to participate**

The protocol for the present study was approved by the ethical committee of the Indian Institute of Technology Indore, as well as Choithram Hospital Indore (approval number FD090) and all procedures were performed by following the revised declaration of Helsinki 2000.

**Consent for publication**

Not applicable

**Availability of data and materials**

All-important data are presented in manuscript or in supplementary figures. Some other supporting information those may not be crucial or affecting result interpretation is not included. Moreover, these data can be available from the corresponding author on reasonable request.

**Competing interests**

The authors declare that they have no competing interests

**Funding**

This project was supported by Council of Scientific and Industrial Research grant no 37(1693)/17/EMR-II and Department of Science and Technology as Ramanujan fellowship grant no. SB/S2/RJN-132/20/5. DST-EMR: EMR/2017/001637.

**Authors' contributions**

HCJ coordinated the project and designed experiments. CS, DC and AKJ collected samples from patients. DK, BB, TPV carried out experiments. BB and TPV analyzed data. DK, BB, and TPV wrote the manuscript. All authors revised and approved the manuscript.

**Acknowledgements**
We appreciate Dr. Ashish Kumar Mukhopadhyay (National Institute of Cholera and Enteric Diseases, Kolkata) for providing the Helicobacter pylori strain I10. We also appreciate Sophisticated Instrumentation Centre, IIT Indore for Confocal microscopy and LC-MS facility.

References

1. Yamaoka Y. Mechanisms of disease: *Helicobacter pylori* virulence factors. Nat Rev Gastroenterol Hepatol. 2010;7:629–41.

2. Mishra S. Is Helicobacter pylori good or bad? Eur J Clin Microbiol Infect Dis. 2013;32:301–4.

3. Carroll IM, Khan AA, Ahmed N. Revisiting the pestilence of Helicobacter pylori: insights into geographical genomics and pathogen evolution. Infect Genet Evol J Mol Epidemiol Evol Genet Infect Dis. 2004;4:81-90.

4. Ishihara K, Miura T, Kimizuka R, Ebihara Y, Mizuno Y, Okuda K. Oral bacteria inhibit *Helicobacter pylori* growth. FEMS Microbiol Lett. 1997;152:355-361.

5. Kusters JG, van Vliet AHM, Kuipers EJ. Pathogenesis of *Helicobacter pylori* Infection. Clin Microbiol Rev. 2006;19:449-90.

6. Bravo D, Hoare A, Soto C, Valenzuela MA, Quest AF. *Helicobacter pylori* in human health and disease: Mechanisms for local gastric and systemic effects. World J Gastroenterol. 2018;24:3071-89.

7. Porras-Hurtado L, Ruiz Y, Santos C, Phillips C, Carracedo Á, Lareu M. An overview of STRUCTURE: applications, parameter settings, and supporting software. Front Genet. 2013;4:98.

8. Moodley Y, Linz B, Bond RP, Nieuwoudt M, Soodyall H, Schlebusch CM, et al. Age of the association between Helicobacter pylori and man. PLoS Pathog. 2012;8:e1002693.

9. Brenner H, Rothenbacher D, Arndt V. Epidemiology of stomach cancer. In: Cancer
10. Servarayan Murugesan C, Manickavasagam K, Chandramohan A, Jebaraj A, Jameel ARA, Jain MS, et al. Gastric cancer in India: epidemiology and standard of treatment. Updat Surg. 2018;70:233-9.

11. Singh K, Ghoshal UC. Causal role of Helicobacter pylori infection in gastric cancer: an Asian enigma. World J Gastroenterol WJG. 2006;12:1346.

12. Graham DY, Lu H, Yamaoka Y. African, Asian or Indian enigma, the East Asian Helicobacter pylori: facts or medical myths. J Dig Dis. 2009;10:77-84.

13. Ghoshal UC, Tiwari S, Pandey R, Dhingra S, Ghoshal U, Singh H, et al. Frequency of Helicobacter pylori and CagA Antibody in Patients with Gastric Neoplasms and Controls: The Indian Enigma: 122. Am J Gastroenterol. 2005;100:S64.

14. Gebara ECE, Faria CM, Pannuti C, Chehter L, Mayer MPA, Lima L. Persistence of Helicobacter pylori in the oral cavity after systemic eradication therapy. J Clin Periodontol. 2006;33:329-333.

15. Anand PS, Kamath KP, Anil S. Role of dental plaque, saliva and periodontal disease in Helicobacter pylori infection. World J Gastroenterol WJG. 2014;20:5639-53.

16. Zarić S, Bojić B, Janković Lj, Dapčević B, Popović B, Čakić S, et al. Periodontal Therapy Improves Gastric Helicobacter pylori Eradication. J Dent Res. 2009;88:946-50.

17. Anand PS, Nandakumar K, Shenoy KT. Are dental plaque, poor oral hygiene, and periodontal disease associated with Helicobacter pylori infection? J Periodontol. 2006;77:692-698.

18. Marsh PD. Controlling the oral biofilm with antimicrobials. J Dent. 2010;38:S11-5.

19. Baehni PC, Takeuchi Y. Anti-plaque agents in the prevention of biofilm-associated oral diseases. Oral Dis. 2003;9:23-9.
20. Backert S, Clyne M, Tegtmeyer N. Molecular mechanisms of gastric epithelial cell adhesion and injection of CagA by Helicobacter pylori. Cell Commun Signal. 2011;9:28.

21. Amieva MR, El-Omar EM. Host-Bacterial Interactions in Helicobacter pylori Infection. Gastroenterology. 2008;134:306-23.

22. Backert S, Tegtmeyer N, Fischer W. Composition, structure and function of the Helicobacter pylori cag pathogenicity island encoded type IV secretion system. Future Microbiol. 2015;10:955-965.

23. Shirin H, Moss SF. Helicobacter pylori induced apoptosis. Gut. 1998;43:592-4.

24. Kauser F, Hussain MA, Ahmed I, Ahmad N, Habeeb A, Khan AA, et al. Comparing genomes of Helicobacter pylori strains from the high-altitude desert of Ladakh, India. J Clin Microbiol. 2005;43:1538-1545.

25. Guo J, Li S, Guo G. Long noncoding RNA AFAP1-AS1 promotes cell proliferation and apoptosis of gastric cancer cells via PTEN/p-AKT pathway. Dig Dis Sci. 2017;62:2004-2010.

26. Canales J, Valenzuela M, Bravo J, Cerda-Opazo P, Jorquera C, Toledo H, et al. Helicobacter pylori induced phosphatidylinositol-3-OH kinase/mTOR activation increases hypoxia inducible factor-1α to promote loss of cyclin D1 and G0/G1 cell cycle arrest in human gastric cells. Front Cell Infect Microbiol. 2017;7:92.

27. Bai Z-G, Ye Y-J, Shen D-H, Lu Y-Y, Zhang Z-T, Wang S. PTEN expression and suppression of proliferation are associated with Cdx2 overexpression in gastric cancer cells. Int J Oncol. 2013;42:1682-1691.

28. Ogden SR, Noto JM, Allen SS, Patel DA, Romero-Gallo J, Washington MK, et al. Matrix Metalloproteinase-7 and Premalignant Host Responses in Helicobacter pylori-Infected Mice. Cancer Res. 2010;70:30-35.
29. Ribble D, Goldstein NB, Norris DA, Shellman YG. A simple technique for quantifying apoptosis in 96-well plates. BMC Biotechnol. 2005;5:12.

30. Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology. 2017;153:420-9.

31. Ramakrishna BS. Helicobacter pylori infection in India: the case against eradication. Indian J Gastroenterol. 2006;25:25.

32. Ansari S, Yamaoka Y. Current understanding and management of Helicobacter pylori infection: an updated appraisal. F1000Research. 2018;7.

33. Datta S, Chattopadhyay S, Patra R, De R, Ramamurthy T, Hembram J, et al. Most Helicobacter pylori strains of Kolkata in India are resistant to metronidazole but susceptible to other drugs commonly used for eradication and ulcer therapy. Aliment Pharmacol Ther. 2005;22:51–7.

34. Thyagarajan S, Ray P, Das BK, Ayyagari A, Khan AA, Dharmalingam S, et al. Geographical difference in antimicrobial resistance pattern of Helicobacter pylori clinical isolates from Indian patients: Multicentric study. J Gastroenterol Hepatol. 2003;18:1373–8.

35. Salles N, Mégraud F. Current management of Helicobacter pylori infections in the elderly. Expert Rev Anti Infect Ther. 2007;5:845–856.

36. Castro-Muñoz LJ, González-Díaz CA, Muñoz-Escobar A, Tovar-Ayona BJ, Aguilar-Anguiano LM, Vargas-Olmos R, et al. Prevalence of Helicobacter pylori from the oral cavity of Mexican asymptomatic children under 5 years of age through PCR. Arch Oral Biol. 2017;73:55–9.

37. Mathur S, Mathur T, Srivastava R, Khatri R. Chlorhexidine: The gold standard in chemical plaque control. Natl J Physiol Pharm Pharmacol. 2011;1:45.
38. Marchetti E, Mummolo S, Di Mattia J, Casalena F, Di Martino S, Mattei A, et al. Efficacy of essential oil mouthwash with and without alcohol: a 3-Day plaque accumulation model. Trials. 2011;12:262.

39. Hu D, Li X, Sreenivasan PK, DeVizio W. A randomized, double-blind clinical study to assess the antimicrobial effects of a cetylpyridinium chloride mouth rinse on dental plaque bacteria. Clin Ther. 2009;31:2540–8.

40. Roopashri G, Jayanthi K, Guruprasad R. Efficacy of benzydamine hydrochloride, chlorhexidine, and povidone iodine in the treatment of oral mucositis among patients undergoing radiotherapy in head and neck malignancies: A drug trail. Contemp Clin Dent. 2011;2:8–12.

41. Rath SK, Singh M. Comparative clinical and microbiological efficacy of mouthwashes containing 0.2% and 0.12% chlorhexidine. Dent Res J. 2013;10:364.

42. Patel R, Gallagher J, Chapple I. Question from practice: how to select the right mouthwash. Acute Pain. 2019;14:44.

43. McGaw WT, Belch A. Oral complications of acute leukemia: prophylactic impact of a chlorhexidine mouth rinse regimen. Oral Surg Oral Med Oral Pathol. 1985;60:275–280.

44. Beji S, Kaaroud H, Ben FM, Abderrahim E, Zghidi S, Ben FH, et al. Acute renal failure following mucosal administration of povidone iodine. Presse Medicale Paris Fr 1983. 2006;35 1 Pt 1:61–63.

45. Gautam SS, Gautam RS. A case of ARF after chromopertubation with povidone iodine. Int J Reprod Contracept Obstet Gynecol. 2018;7:2982–4.

46. Balin AK, Pratt L. Dilute povidone-iodine solutions inhibit human skin fibroblast growth. Dermatol Surg Off Publ Am Soc Dermatol Surg Al. 2002;28:210–4.

47. Pohanish RP. Sittig’s Handbook of Toxic and Hazardous Chemicals and Carcinogens.
48. Antignac E, Nohynek GJ, Re T, Clouzeau J, Toutain H. Safety of botanical ingredients in personal care products/cosmetics. Food Chem Toxicol. 2011;49:324-41.

49. Reisfield GM, Goldberger BA, Pesce AJ, Crews BO, Wilson GR, Teitelbaum SA, et al. Ethyl glucuronide, ethyl sulfate, and ethanol in urine after intensive exposure to high ethanol content mouthwash. J Anal Toxicol. 2011;35:264-268.

50. Jones CG. Chlorhexidine: is it still the gold standard? Periodontol 2000. 1997;15:55-62.

51. Patwardhan GA, Beverly LJ, Siskind LJ. Sphingolipids and mitochondrial apoptosis. J Bioenerg Biomembr. 2016;48:153-168.

52. Gryko M, Pryczynicz A, Zareba K, Kędra B, Kemona A, Guzińska-Ustymowicz K. The expression of Bcl-2 and BID in gastric cancer cells. J Immunol Res. 2014;2014.

53. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 2008;9:47-59.

54. Blanchard TG, Nedrud JG. Laboratory maintenance of Helicobacter species. Curr Protoc Microbiol. 2012;24:8B-1.

55. Chachaty E, Saulnier P. Bacterial DNA Extraction for Polymerase Chain Reaction and Pulsed-Field Gel Electrophoresis. In: Nucleic Acid Protocols Handbook, The. New Jersey: Humana Press; 2000. p. 33-6. doi:10.1385/1-59259-038-1:33.

56. Jha HC, Lu J, Saha A, Cai Q, Banerjee S, Prasad MAJ, et al. EBNA3C-Mediated Regulation of Aurora Kinase B Contributes to Epstein-Barr Virus-Induced B-Cell Proliferation through Modulation of the Activities of the Retinoblastoma Protein and Apoptotic Caspases. J Virol. 2013;87:12121-38.

Figures
Identification of bacteria through gram staining. Gram staining of different clinical isolates of H. Pylori namely; I10, HJ9, HB10, HJ10, HB14, HJ14, HB1, HJ1, HB4 and HB5 showing typical gram-negative bacteria.

Figure 2
Growth pattern of isolated H. pylori strains. (a) The growth pattern of clinical isolates (HJ1,
HB1, HB4, HB5, HJ9, HJ10, HB10, HJ14, HB14) and reference strain (I10) under specific microaerophilic condition assessed at 0, 6, 12, 18 and 24hrs. The data are the mean ±SD (n=4) of two independent experiments with technical replicate. (b): Graphs are plotted for relative growth in comparison to I10 at 0, 2, 6, 12, 18 and 24hrs. (c) Plate densitometry image of selected H. pylori isolates HB1 (lane 1st); HB5 (lane 2nd); HB14 (lane 3rd); HJ9 (lane 4th); and I10 (lane 5th) are showing growth till 24hrs. The experiment is performed in duplicates and the representative images are shown. (d) Fold change calculated in comparison to 0 Hr
Growth pattern of *H. pylori* isolates after chemical treatment for 30sec. Treatment of chemicals (A, B, C, D and E) was given to 6X10^7 of *H. pylori* for 30sec and growth was observed until 24hrs compared to untreated control. Graphs reflect the growth of (a) fast (HB1 and HB5) and (b) slow growing (HJ9, HB14 and I10) isolates. Relative growth of (c) HB1, (d) HB5 (e) I10 was estimated compared to untreated control. The data are the mean ±SD of two independent experiments with technical replicate (n=4, mean ± SD).
Treatment with selected chemicals for a shorter duration. 6×10^7 of H. pylori were treated with selected chemicals alone and in combination (B, D, E, BD, BE, DE and BDE) for 5 sec. Growth was observed until 24 hrs in comparison to untreated control. Growth curve of (a) fast growing isolates (HB1 and HB5) and (b) slow growing isolates (HJ9, HB14 and I10). Relative growth of HB1, HB5, I10, HJ9 and HB14 compared to untreated control. The data are the mean ±SD of two independent experiments with technical replicate (n=4, mean ±SD).
Plate densitometry of H. pylori after chemical treatment. Chemical treatment of A, B, C, D and E was given to 1X10^7 H. pylori followed by spreading on half of the BHI Agar plate. Representative images showing growth of (a) HB1, (b) HB5, (c) I10 (d) HJ9 and (e) HB14 till 24hrs. Relative growth was estimated for fast growing isolates (f) HB1 and (g) HB5; and slow growing isolates (h) I10, (i) HJ9 and (j) HB14. Blank plates were considered as negative control and untreated isolates as a positive control. The data are the mean ±SD of two independent experiments with technical replicate (n=4, mean ±SD)
Investigation of \( \text{H. pylori} \) and gastric cancer genes: Treatment of chemical was given to \( 6 \times 10^7 \) of \( \text{H. pylori} \) and incubated with \( 0.5 \times 10^6 \) AGS cell for 12 Hrs. RNA was isolated and transcript level was determined by qRTPCR. Experiments were performed in duplicates. Expression of 16s rRNA (a,b); CagA (c,d); BabA (e,f); CCND1 (g,h); CDX2 (i,j); PTEN (k,l); MMP7 (m,n) was evaluated on 5 and 30 sec treatment respectively.
Figure 7

EB/AO dual staining assay. 0.25X10^6 AGS cells were plated in 6 well plates and infected with 30 sec chemical (A, B, C, D and E) treated and wild type (WT) H. pylori isolates. Furthermore, 12 hrs post-infection the cells were stained with EB/AO solution and images were acquired. (a) HB1, (b) I10, (c) HJ9 and (d) HB14 infected and uninfected AGS cells
Figure 8

Status of apoptosis-related genes. Chemical treatment was given to 6X10^7 of H. pylori and incubated with 0.5X10^6 AGS cell for 12 Hrs. RNA was isolated and the transcript level was determined by qRTPCR. Experiments were performed in duplicates. Expression of (a, b) FADD; (c, d) APAF1; (e, f) BAK; (g, h) BID; (i, j) PUMA; (k, l) NOXA; and (m, n) Bcl2 was assessed after treatment for 5 and 30 sec respectively. The data are the mean ± SEM of two independent experiments with technical replicate (n=4)

Supplementary Files
This is a list of supplementary files associated with this preprint. Click to download.
Supplementary Figures-BMC Microbiology.pdf